1. Volume 68, Issue 6, Pages e129-e131 (December 2015)
Re: Orazio Caffo, Ugo De Giorgi, Lucia Fratino, et al. Clinical Outcomes of Castration- resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. Eur Urol 2015;68:147–53 
Kevin Lu 
European Urology 
Volume 68, Issue 6, Pages e129-e131 (December 2015)
DOI: /j.eururo
Copyright © 2015 European Association of Urology Terms and Conditions

2. Fig. 1
(A) Hypothetical clinical outcome of metastatic castration-resistant prostate cancer evaluated on the basis of Response Evaluation Criteria in Solid Tumors (RECIST). (B) Hypothetically estimated progression-free survival [4,5] of patients receiving sequential therapy.
ABI=abiraterone; CBZ=cabazitaxel; DOC=docetaxel; ENZ=enzalutamide; ePFS=estimated progression-free survival; L=line of therapy; PSA=prostate-specific antigen; SIP=sipuleucel-T.
European Urology  , e129-e131DOI: ( /j.eururo )
Copyright © 2015 European Association of Urology Terms and Conditions